XML 41 R27.htm IDEA: XBRL DOCUMENT
v3.19.2

Organization and Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2019
Reconciliation of Deferred Revenue Balances | A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
|  | Years Ended June 30, |
|  | 2019 |  |  | 2018 |
Deferred revenue - beginning balance |  | $ | 2.6 |  |  | $ | 2.6 |
Revenue recognized |  |  | (7.9 | ) |  |  | (14.0 | )
Prepayments |  |  | 7.5 |  |  |  | 14.0 |
Deferred revenue - ending balance |  | $ | 2.2 |  |  | $ | 2.6 |
Schedule of Company's Revenue by Type | The following table represents the Company’s revenue by type for the years ended June 30, 2019, 2018 and 2017 (in thousands):
|  | Years Ended June 30, |
(In millions) |  | 2019 |  |  | 2018 (a) |  |  | 2017 (a) |
Molecular diagnostic revenues: |  |  |  |  |  |  |  |  |  |  |  |
Hereditary Cancer Testing |  | $ | 479.7 |  |  | $ | 471.4 |  |  | $ | 525.5 |
GeneSight |  |  | 112.6 |  |  |  | 124.9 |  |  |  | 78.4 |
Prenatal |  |  | 104.9 |  |  |  | — |  |  |  | — |
Vectra |  |  | 48.3 |  |  |  | 55.2 |  |  |  | 45.2 |
Prolaris |  |  | 25.5 |  |  |  | 21.5 |  |  |  | 11.1 |
EndoPredict |  |  | 10.4 |  |  |  | 8.8 |  |  |  | 7.7 |
Other |  |  | 8.0 |  |  |  | 8.6 |  |  |  | 11.5 |
Total molecular diagnostic revenue |  |  | 789.4 |  |  |  | 690.4 |  |  |  | 679.4 |
Pharmaceutical and clinical service revenue |  |  | 61.7 |  |  |  | 53.3 |  |  |  | 49.3 |
Total revenue |  | $ | 851.1 |  |  | $ | 743.7 |  |  | $ | 728.7 |
| (a) | Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606)
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations | The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:
|  | Years Ended June 30, |
|  | 2019 |  |  | 2018 |  |  | 2017 |
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average shares outstanding used to compute basic EPS |  |  | 73.5 |  |  |  | 69.4 |  |  |  | 68.3 |
Effect of dilutive stock options |  |  | 2.5 |  |  |  | 2.6 |  |  |  | 0.5 |
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS |  |  | 76.0 |  |  |  | 72.0 |  |  |  | 68.8 |
Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation | These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
|  | Years Ended June 30, |
|  | 2019 |  |  | 2018 |  |  | 2017 |
Anti-dilutive options and RSUs excluded from EPS computation |  |  | 0.8 |  |  |  | — |  |  |  | 7.0 |
ASC 606 |
Schedule of Recast of Certain Prior Period Amounts to Conform with the Adoption of Topic 606 | The Company recast certain prior period amounts to conform with the adoption of Topic 606, as shown in the table below (in thousands):
|  | FY2018 |  |  | FY2017 |
|  | As Reported |  |  | Adjusted for ASC 606 |  |  | As Adjusted |  |  | As Reported |  |  | Adjusted for ASC 606 |  |  | As Adjusted |
Total revenue |  | $ | 772.6 |  |  | $ | (28.9 | ) |  | $ | 743.7 |  |  | $ | 769.9 |  |  | $ | (41.2 | ) |  | $ | 728.7 |
Selling, general, and administrative expense |  |  | 467.1 |  |  | $ | (32.1 | ) |  |  | 435.0 |  |  |  | 476.4 |  |  | $ | (36.5 | ) |  |  | 439.9 |
Income tax provision |  |  | (14.0 | ) |  | $ | 1.0 |  |  |  | (13.0 | ) |  |  | 20.6 |  |  | $ | (1.6 | ) |  |  | 19.0 |
Net income attributable to Myriad Genetics, Inc. stockholders |  |  | 131.1 |  |  | $ | 2.2 |  |  |  | 133.3 |  |  |  | 20.5 |  |  | $ | (3.1 | ) |  |  | 17.4 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 1.89 |  |  | $ | 0.03 |  |  | $ | 1.92 |  |  | $ | 0.30 |  |  | $ | (0.05 | ) |  | $ | 0.25 |
Diluted |  | $ | 1.82 |  |  | $ | 0.03 |  |  | $ | 1.85 |  |  | $ | 0.30 |  |  | $ | (0.05 | ) |  | $ | 0.25 |
|  | FY2018 |  |  | FY2017 |
|  | As Reported |  |  | Adjusted for ASC 606 |  |  | As Adjusted |  |  | As Reported |  |  | Adjusted for ASC 606 |  |  | As Adjusted |
Trade accounts receivable |  | $ | 98.3 |  |  | $ | 1.2 |  |  | $ | 99.5 |  |  | $ | 90.2 |  |  | $ | (1.0 | ) |  | $ | 89.2 |
Retained earnings |  |  | 52.9 |  |  |  | 1.2 |  |  |  | 54.1 |  |  |  | (78.2 | ) |  |  | (1.0 | ) |  |  | (79.2 | )
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] |
Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Income/(Loss) | The following table shows the cumulative translation adjustments included in accumulated other comprehensive income/(loss):
Ending balance June 30, 2018 |  | $ | (4.1 | )
Period translation adjustments |  |  | (3.1 | )
Ending balance June 30, 2019 |  |  | (7.2 | )

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of accumulated other comprehensive income (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580 + Details
Name: | us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e765-108305 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.10-01.(b)(6)) -URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=109236672&loc=d3e725-108305 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 + Details
Name: | us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |